About Hemispherx Biopharma (NYSEAMERICAN:HEB)
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's approved products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of sexually transmitted disease infection; and Ampligen, a product approved for sale in Argentina for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma; Alferon N Injection for the treatment of various categories of genital warts; and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of pandemic influenza, seasonal influenza, and other viruses. The company was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:HEB
CUSIPN/A
Phone+1-407-2718516
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-1,391.11%
Return on Equity-49.30%
Return on Assets-32.57%
Miscellaneous
EmployeesN/A
Outstanding Shares37,720,000
Hemispherx Biopharma (NYSEAMERICAN:HEB) Frequently Asked Questions
What is Hemispherx Biopharma's stock symbol?
Hemispherx Biopharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "HEB."
How were Hemispherx Biopharma's earnings last quarter?
Hemispherx Biopharma (NYSEAMERICAN:HEB) announced its quarterly earnings results on Monday, April, 2nd. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter. The specialty pharmaceutical company had revenue of $0.05 million for the quarter. Hemispherx Biopharma had a negative net margin of 1,391.11% and a negative return on equity of 49.30%. View Hemispherx Biopharma's Earnings History.
Are investors shorting Hemispherx Biopharma?
Hemispherx Biopharma saw a increase in short interest in the month of March. As of March 29th, there was short interest totalling 1,151,647 shares, an increase of 2.5% from the March 15th total of 1,123,857 shares. Based on an average daily volume of 341,930 shares, the days-to-cover ratio is currently 3.4 days. Currently, 3.2% of the shares of the stock are short sold.
Who are some of Hemispherx Biopharma's key competitors?
Some companies that are related to Hemispherx Biopharma include Rexahn Pharmaceuticals (RNN), Abzena (ABZA), Scancell (SCLP), DiaMedica Therapeutics (DMA), Antibe Therapeutics (ATE), Ceapro (CZO), Nuvo Pharmaceuticals (NRI), NetScientific (NSCI), Actinium Pharmaceuticals (ATNM), Quetzal Energy (KALTF), BiOasis Technologies (BTI), Factor Therapeutics (FTT), Prana Biotechnology (PBT), Pediapharm (PDP) and iBioPharma (IBIO).
Who are Hemispherx Biopharma's key executives?
Hemispherx Biopharma's management team includes the folowing people:
- Mr. Thomas K. Equels Esq., M.S., J.D., Exec. Vice Chairman, CEO & Pres (Age 65)
- Mr. Adam Pascale CPA, CFO & Chief Accounting Officer (Age 70)
- Dr. David R. Strayer M.D., Chief Scientific Officer & Medical Director (Age 72)
- Mr. Wayne S. Springate, Sr. VP of Operations (Age 47)
- Ann Marie E. Coverly, Director of Admin. & HR and Deputy Investor Relations Coordinator
Has Hemispherx Biopharma been receiving favorable news coverage?
Headlines about HEB stock have trended somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Hemispherx Biopharma earned a coverage optimism score of 0.12 on Accern's scale. They also gave news coverage about the specialty pharmaceutical company an impact score of 45.99 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of Hemispherx Biopharma?
Shares of HEB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Hemispherx Biopharma's stock price today?
One share of HEB stock can currently be purchased for approximately $0.33.
How big of a company is Hemispherx Biopharma?
Hemispherx Biopharma has a market capitalization of $14.21 million.
How can I contact Hemispherx Biopharma?
Hemispherx Biopharma's mailing address is 860 N Orange Ave Ste B, ORLANDO, FL 32801-5205, United States. The specialty pharmaceutical company can be reached via phone at +1-407-2718516.
MarketBeat Community Rating for Hemispherx Biopharma (HEB)
MarketBeat's community ratings are surveys of what our community members think about Hemispherx Biopharma and other stocks. Vote "Outperform" if you believe HEB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HEB will underperform the S&P 500 over the long term. You may vote once every thirty days.
Hemispherx Biopharma (NYSEAMERICAN:HEB) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
(Data available from 4/23/2016 forward)
Hemispherx Biopharma (NYSEAMERICAN:HEB) Earnings History and Estimates Chart
Hemispherx Biopharma (NYSEAMERICAN HEB) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 4/2/2018 | Q4 2017 | | ($0.06) | | $0.05 million | View | N/A |  |
| 11/15/2017 | Q3 2017 | | ($0.04) | | $0.09 million | View | N/A | |
| 8/14/2017 | Q2 2017 | | ($0.08) | | $0.21 million | View | N/A | |
| 5/15/2017 | Q1 2017 | | ($0.11) | | $0.08 million | View | N/A | |
| 3/31/2017 | Q4 2016 | | ($0.04) | | $0.02 million | View | N/A | |
| 11/14/2016 | Q3 16 | | ($0.30) | | $0.02 million | View | N/A | |
| 8/15/2016 | Q216 | | ($0.01) | | $0.02 million | View | N/A | |
| 5/16/2016 | Q116 | | ($0.01) | $40.99 million | $0.04 million | View | N/A | |
| 3/29/2016 | Q4 2015 | | ($0.12) | | $0.03 million | View | N/A | |
| 11/17/2015 | Q3 2015 | | ($0.24) | | $0.02 million | View | N/A | |
| 8/13/2015 | Q2 | | ($0.02) | | $0.05 million | View | N/A | |
| 5/13/2015 | Q1 15 | | ($0.02) | | $0.04 million | View | N/A | |
| 3/20/2015 | Q4 2014 | | ($0.24) | | $0.04 million | View | N/A | |
| 11/10/2014 | Q3 2014 | | ($0.24) | | $0.05 million | View | N/A | |
| 8/11/2014 | Q2 2014 | | ($0.36) | | $0.04 million | View | N/A | |
| 5/9/2014 | Q1 2014 | | ($0.24) | | $0.08 million | View | N/A | |
| 3/14/2014 | Q4 2013 | | ($0.24) | | $0.04 million | View | N/A | |
| 11/8/2013 | Q3 2013 | | ($0.36) | | $0.04 million | View | N/A | |
| 8/9/2013 | Q2 2013 | | ($0.03) | | $0.04 million | View | N/A | |
| 5/8/2013 | Q1 2013 | | ($0.24) | | $0.04 million | View | N/A | |
| 3/18/2013 | Q4 2012 | | ($0.36) | | | View | N/A | |
| 11/5/2012 | Q312 | | ($0.04) | | | View | N/A | |
| 8/8/2012 | Q2 2012 | | ($0.26) | | | View | N/A | |
| 5/7/2012 | Q1 2012 | ($0.36) | ($0.20) | | | View | N/A | |
| 3/14/2012 | Q4 2011 | | ($0.31) | | | View | N/A | |
| 11/9/2011 | Q3 2011 | ($0.24) | ($0.30) | | | View | N/A | |
| 8/5/2011 | Q2 2011 | ($0.36) | ($0.31) | | | View | N/A | |
| 5/6/2011 | Q1 2011 | ($0.24) | ($0.07) | | | View | N/A | |
| 3/29/2011 | Q4 2010 | ($0.36) | ($0.24) | | | View | N/A | |
| 11/8/2010 | Q3 2010 | ($0.36) | ($0.29) | | | View | N/A | |
| 8/6/2010 | Q2 2010 | ($0.36) | ($0.36) | | | View | N/A | |
| 5/7/2010 | Q1 2010 | | ($0.36) | | | View | N/A | |
| 3/15/2010 | Q4 2009 | ($0.24) | ($0.36) | | | View | N/A | |
| 11/9/2009 | Q3 2009 | | ($0.24) | | | View | N/A | |
| 8/10/2009 | Q2 2009 | | ($0.47) | | | View | N/A | |
| 5/12/2009 | Q1 2009 | | ($0.47) | | | View | N/A | |
| 3/16/2009 | Q4 2008 | | ($0.36) | | | View | N/A | |
| 11/10/2008 | Q3 2008 | | ($0.60) | | | View | N/A | |
| 8/12/2008 | Q2 2008 | | ($0.48) | | | View | N/A | |
| 5/12/2008 | Q1 2008 | | ($0.48) | | | View | N/A | |
| 3/17/2008 | Q4 2007 | | ($0.60) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Hemispherx Biopharma (NYSEAMERICAN:HEB) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Hemispherx Biopharma (NYSEAMERICAN HEB) Insider Trading and Institutional Ownership History
Hemispherx Biopharma (NYSEAMERICAN HEB) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/2/2017 | Adam Pascale | CFO | Buy | 15,873 | $0.63 | $9,999.99 | 27,389 | |
| 5/2/2017 | David R Strayer | Insider | Buy | 7,937 | $0.63 | $5,000.31 | 41,804 | |
| 4/27/2017 | Thomas K Equels | CEO | Buy | 72,464 | $0.69 | $50,000.16 | 492,919 | |
| 4/11/2017 | Thomas K Equels | CEO | Buy | 200,000 | $0.50 | $100,000.00 | 420,455 | |
| 2/16/2017 | Adam Pascale | CFO | Buy | 6,981 | $0.46 | $3,211.26 | 11,516 | |
| 2/16/2017 | David R Strayer | Insider | Buy | 9,892 | $0.46 | $4,550.32 | 33,867 | |
| 2/16/2017 | Wayne S Springate | SVP | Buy | 8,014 | $0.46 | $3,686.44 | 31,989 | |
| 12/22/2016 | Thomas K Equels | CEO | Buy | 68,493 | $0.73 | $49,999.89 | 220,455 | |
| 11/1/2016 | Thomas K Equels | CEO | Buy | 10,000 | $1.00 | $10,000.00 | 151,962 | |
| 7/8/2016 | Thomas K Equels | CEO | Buy | 48,000 | $0.12 | $5,760.00 | 1,703,548 | |
| 7/1/2016 | Thomas K Equels | CEO | Buy | 171,000 | $0.12 | $20,520.00 | 1,514,548 | |
| 3/18/2016 | Thomas K Equels | CEO | Buy | 30,000 | $0.13 | $3,900.00 | 1,484,548 | |
| 3/11/2016 | Thomas K Equels | CEO | Buy | 40,000 | $0.16 | $6,400.00 | 1,444,548 | |
| 3/10/2016 | Thomas K Equels | CEO | Buy | 30,000 | $0.16 | $4,800.00 | 30,000 | |
| 8/20/2015 | William A Carter | CEO | Buy | 25,000 | $0.18 | $4,500.00 | 1,225,585 | |
| 8/18/2015 | William A Carter | CEO | Buy | 25,000 | $0.18 | $4,500.00 | 1,200,585 | |
| 8/17/2015 | William A Carter | CEO | Buy | 25,000 | $0.18 | $4,500.00 | | |
| 8/14/2015 | Thomas K Equels | CFO | Buy | 79,104 | $0.18 | $14,238.72 | | |
| 4/28/2015 | William A Carter | CEO | Buy | 100,000 | $0.24 | $24,000.00 | | |
| 4/27/2015 | Thomas K Equels | CFO | Buy | 100,000 | $0.24 | $24,000.00 | | |
| 4/21/2015 | William A Carter | CEO | Buy | 100,000 | $0.24 | $24,000.00 | | |
| 4/20/2015 | Thomas K Equels | CFO | Buy | 100,000 | $0.24 | $24,000.00 | | |
| 4/17/2015 | William A Carter | CEO | Buy | 73,681 | $0.23 | $16,946.63 | | |
| 4/16/2015 | William A Carter | CEO | Buy | 26,319 | $0.23 | $6,053.37 | | |
| 4/15/2015 | Thomas K Equels | CFO | Buy | 100,000 | $0.23 | $23,000.00 | | |
(Data available from 1/1/2013 forward)
Hemispherx Biopharma (NYSEAMERICAN HEB) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Hemispherx Announces Pricing of $2.57 Million Registered Direct Offering at a Premium to Market
finance.yahoo.com - April 20 at 5:28 PM |
| Wired News – ArQule Inked Exclusive License Deal with Basilea for Derazantinib in the US, EU, Japan and Rest of World
finance.yahoo.com - April 19 at 8:08 AM |
| Hemispherx Successfully Completes Production of More Than 8,500 Vials of Ampligen for Commercial Sales and Expanded Clinical Programs
finance.yahoo.com - April 17 at 6:05 PM |
 | Investors & Innovators to Come Together at BioNJ's BioPartnering Conference with JP Morgan
www.businesswire.com - April 15 at 8:59 AM |
 | Short Interest in Hemispherx BioPharma, Inc (HEB) Expands By 2.5%
www.americanbankingnews.com - April 11 at 3:20 AM |
| Hemispherx Expands Ampligen Early Access Programme to Canada to Treat ME/CFS Patients
finance.yahoo.com - April 4 at 4:21 PM |
| Hemispherx Biopharma Announced Financial Results for the Year Ended December 31, 2017
finance.yahoo.com - April 2 at 5:33 PM |
| Hemispherx BioPharma, Inc (HEB) Short Interest Down 43.2% in March
www.americanbankingnews.com - March 27 at 1:54 AM |
 | Hemispherx Biopharma and UNMC Partner to Take on Pancreatic Cancer - GlobeNewswire (press release)
globenewswire.com - March 15 at 8:08 AM |
| Hemispherx Biopharma and UNMC Partner to Take on Pancreatic Cancer
finance.yahoo.com - March 14 at 7:16 PM |
| Hemispherx BioPharma, Inc (HEB) Sees Significant Increase in Short Interest
www.americanbankingnews.com - March 9 at 6:22 PM |
| Hemispherx to Present at the 30th Annual ROTH Conference - GlobeNewswire (press release)
globenewswire.com - March 6 at 8:08 AM |
| Hemispherx to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 5 at 5:55 PM |
| Hemispherx BioPharma, Inc (HEB) Short Interest Down 10.6% in February
www.americanbankingnews.com - February 28 at 1:56 AM |
| Hemispherx to Present at the Inaugural LD Micro Virtual Conference
finance.yahoo.com - February 27 at 6:00 PM |
| Hemispherx To Supply Ampligen for Pancreatic Cancer Patients in Canada Under Special Access Program - GlobeNewswire (press release)
globenewswire.com - February 27 at 8:11 AM |
| Hemispherx To Supply Ampligen for Pancreatic Cancer Patients in Canada Under Special Access Program
finance.yahoo.com - February 26 at 5:50 PM |
 | Technical Perspectives on Biotech Stocks -- Grifols, Heat Biologics, Hemispherx Biopharma, and iBio - PR Newswire (press release)
www.prnewswire.com - February 10 at 3:40 PM |
| Short Interest in Hemispherx BioPharma, Inc (HEB) Expands By 13.7%
www.americanbankingnews.com - February 9 at 8:06 PM |
 | Longtime Philadelphia biotech firm leaves the city
www.bizjournals.com - January 31 at 3:38 PM |
| Hemispherx’s Ampligen Highlighted in Review of Role of TLR3 Agonist Support for “Universal” Flu Immunization Development Programs
finance.yahoo.com - January 31 at 8:52 AM |
| Hemispherx to Present at the BIO CEO & Investor Conference
finance.yahoo.com - January 29 at 8:49 AM |
| Hemispherx Announces Presentation on the Potential Role of Ampligen as an Immune System Amplifier Improving Seasonal Flu Vaccine Cross-Protection
finance.yahoo.com - January 26 at 3:38 PM |
 | Hemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes with Checkpoint ... - Nasdaq
www.nasdaq.com - January 25 at 3:39 PM |
| Hemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes with Checkpoint Inhibitors
finance.yahoo.com - January 25 at 8:45 AM |
| Hemispherx BioPharma, Inc (HEB) Sees Large Growth in Short Interest
www.americanbankingnews.com - January 24 at 6:08 PM |
| HEB: Recent Advancements…What Do They Imply?
finance.yahoo.com - January 24 at 3:45 PM |
| Hemispherx Comments on $500+ Million Market Opportunity for Ampligen®, the Only Late Stage ME/CFS Candidate in the U.S.
finance.yahoo.com - January 23 at 4:58 PM |
| Here's Why the 2 Latest Hemispherx BioPharma Announcements Are Important
finance.yahoo.com - January 19 at 3:49 PM |
| Hemispherx Enters into Sale/Leaseback Agreement for NJ Development and Production Facility
finance.yahoo.com - January 17 at 11:18 AM |
| Hemispherx Enhances Manufacturing Efficiency of Ampligen - Nasdaq
www.nasdaq.com - January 12 at 11:19 AM |
| Hemispherx Enhances Manufacturing Efficiency of Ampligen - GlobeNewswire (press release)
globenewswire.com - January 11 at 3:40 PM |
| Hemispherx BioPharma, Inc (HEB) Short Interest Update
www.americanbankingnews.com - January 11 at 2:36 AM |
| Hemispherx Biopharma CEO Discusses 2017 Highlights on CEOLIVE.TV - GlobeNewswire (press release)
globenewswire.com - January 4 at 3:39 PM |
| Hemispherx Biopharma, Inc. Discusses Clinical Development and Approval in Argentina in New SNNLive Video Interview on StockNewsNow.com
finance.yahoo.com - January 3 at 10:50 AM |
| Hemispherx Biopharma CEO Discusses 2017 Highlights on CEOLIVE.TV
finance.yahoo.com - January 2 at 11:06 AM |
| Hemispherx Biopharma, Inc. to Present at Biotech Showcase ... - GlobeNewswire (press release)
globenewswire.com - December 30 at 3:39 PM |
| Short Interest in Hemispherx BioPharma, Inc (HEB) Expands By 2.1%
www.americanbankingnews.com - December 29 at 1:28 AM |
| ETFs with exposure to Hemispherx Biopharma, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 12:41 PM |
| Hemispherx Successfully Completes Commercial Scale Demonstration Batch of Ampligen® at Contract Manufacturer - GlobeNewswire (press release)
globenewswire.com - December 20 at 3:38 PM |
| Hemispherx Successfully Completes Commercial Scale Demonstration Batch of Ampligen® at Contract Manufacturer
finance.yahoo.com - December 20 at 11:27 AM |
| ETFs with exposure to Hemispherx Biopharma, Inc. : December 15, 2017
finance.yahoo.com - December 15 at 3:43 PM |
| Short Interest in Hemispherx Biopharma, Inc. (HEB) Increases By 7.0%
www.americanbankingnews.com - December 11 at 7:58 PM |
| ETFs with exposure to Hemispherx Biopharma, Inc. : December 5, 2017
finance.yahoo.com - December 5 at 1:02 PM |
| Hemispherx Biopharma, Inc. (HEB) Short Interest Up 4.2% in November
www.americanbankingnews.com - November 28 at 1:04 AM |
| Hemispherx BioPharma, Inc (HEB) Releases Earnings Results
www.americanbankingnews.com - November 16 at 6:44 PM |
| Hemispherx Biopharma, Inc. CEO Interviewed on CEOLIVE.TV - GlobeNewswire (press release)
globenewswire.com - November 16 at 4:02 PM |
 | Hemispherx Biopharma, Inc. CEO Interviewed on CEOLIVE.TV
feeds.benzinga.com - November 15 at 9:57 AM |
| HEB: Will The Current Improvements Cause A Turnaround For Hemispherx?
finance.yahoo.com - November 14 at 3:51 PM |
Hemispherx Biopharma (NYSEAMERICAN:HEB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Hemispherx Biopharma (NYSEAMERICAN:HEB) Income Statement, Balance Sheet and Cash Flow Statement
Hemispherx Biopharma (NYSEAMERICAN HEB) Stock Chart for Monday, April, 23, 2018
Loading chart…
